Sanofi, a leading global biopharmaceutical company, is committed to addressing global health challenges by improving access to medicines and focusing on sustainable practices. The company has made significant progress in reducing its carbon emissions, with a goal to achieve net-zero emissions by 2050. Sanofi’s ESG rating is bolstered by its commitment to health equity and the development of treatments for critical conditions. However, Sanofi has faced criticism over drug pricing practices and its past involvement in issues related to vaccine access. Its ESG score reflects positive environmental and social contributions, but concerns over governance and accessibility of its treatments persist. The latest Sanofi ESG report provides further details on the company’s sustainability and health impact efforts.